TSX Exchange Symbol: RVX
CALGARY, Oct. 4 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is
pleased to announce today that the Company is making an oral presentation of
key scientific data of its lead clinical candidate, RVX-208, at the 16th
International Symposium for Drugs Affecting Lipid Metabolism (DALM). The
presentation titled, "A novel drug RVX-208 raises plasma apolipoprotein A-l
and HDL cholesterol", will be presented by Dr. Norman Wong on October 4, 2007
at the Hilton Hotel in New York City.
"DALM is a premier international conference renowned for its content of
state of the art therapeutics for the prevention of atherosclerosis and other
cardiovascular diseases. We are pleased that Resverlogix will present its data
detailing RVX-208, a small molecule drug which enhances the production of
ApoA-l and HDL," stated Dr. Jan Johansson, Senior Vice President of Clinical
Affairs of Resverlogix. Dr. Johansson added, "The scientific community
recognizes the importance of a small molecule in the form of an oral tablet
that significantly increases ApoA-I production, thereby enhancing the function
of HDL. These beneficial effects of RVX-208 will potentially reduce the risk
of atherosclerosis and cardiovascular disease."
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-l. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
Note to editors: Ken Lebioda, Senior Vice-President, will be attending
the conference and can meet in person with interested media.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com, Website: www.resverlogix.com